USA - engelsk - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefprozil (unii: 4w0459za4v) (cefprozil anhydrous - unii:1m698f4h4e) - cefprozil anhydrous 250 mg - cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: caused by streptococcus pyogenes . note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefprozil is generally effective in the eradication of streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. caused by streptococcus pneumoniae, haemophilus influenzae (including ß-lactamase-producing strains), and moraxella (branhamella) catarrhalis (including ß-lactamase-producing strains). (see clinical studies.) note: in the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. in considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. caused by streptococcus pneumoniae , haemophilus influenzae (including ß-lactamase producing strains), and moraxella (branhamella) catarrhalis (including ß-lactamase-producing strains). caused by streptococcus pneumoniae, haemophilus influenzae (including ß-lactamase-producing strains), and moraxella (branhamella) catarrhalis (including ß-lactamase-producing strains). caused by staphylococcus aureus (including penicillinase-producing strains) and streptococcus pyogenes . abscesses usually require surgical drainage. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefprozil is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

Canada - fransk - Health Canada

auro pharma inc - cefprozil (monohydrate de cefprozil) - poudre pour suspension - 125mg - cefprozil (monohydrate de cefprozil) 125mg - second generation cephalosporins

Canada - fransk - Health Canada

auro pharma inc - cefprozil (monohydrate de cefprozil) - poudre pour suspension - 250mg - cefprozil (monohydrate de cefprozil) 250mg - second generation cephalosporins

Canada - fransk - Health Canada

sun pharma canada inc - cefprozil (monohydrate de cefprozil) - comprimé - 250mg - cefprozil (monohydrate de cefprozil) 250mg - second generation cephalosporins

Canada - fransk - Health Canada

sun pharma canada inc - cefprozil (monohydrate de cefprozil) - comprimé - 500mg - cefprozil (monohydrate de cefprozil) 500mg - second generation cephalosporins

Canada - engelsk - Health Canada

auro pharma inc - cefprozil (cefprozil monohydrate) - powder for suspension - 125mg - cefprozil (cefprozil monohydrate) 125mg - second generation cephalosporins

Canada - engelsk - Health Canada

auro pharma inc - cefprozil (cefprozil monohydrate) - powder for suspension - 250mg - cefprozil (cefprozil monohydrate) 250mg - second generation cephalosporins

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefprozil (unii: 4w0459za4v) (cefprozil anhydrous - unii:1m698f4h4e) - cefprozil anhydrous 500 mg - cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: caused by streptococcus pyogenes . note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefprozil is generally effective in the eradication of streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. caused by streptococcus pneumoniae, haemophilus influenzae (including ß-lactamase-producing strains), and moraxella (branhamella) catarrhalis (including ß-lactamase-producing strains). (see clinical studies.) note: in the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observe

USA - engelsk - NLM (National Library of Medicine)

rising health, llc - cefprozil (unii: 4w0459za4v) (cefprozil anhydrous - unii:1m698f4h4e) - cefprozil anhydrous 125 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: upper respiratory tract pharyngitis/tonsillitis caused by streptococcus pyogenes . note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefproz

USA - engelsk - NLM (National Library of Medicine)

northstar rx llc - cefprozil (unii: 4w0459za4v) (cefprozil anhydrous - unii:1m698f4h4e) - cefprozil anhydrous 125 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil  and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: upper respiratory tract pharyngitis/tonsillitis caused by streptococcus pyogenes . note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefprozil